<< Back to Summary 
The USA House of Representatives Committee on Energy and Commerce and its Subcommittee on Oversight and Investigations are probing the Vytorin-ENHANCE controversy by studying the “withholding of clinical trial data that may significantly affect the medical management of hypercholesterolemia, as well as the use of misleading statement in direct-to-consumer advertisements for prescription medicines.” Do you believe that this investigation is worthwhile?
#Response DateOther (please specify)
1.4/22/2008 5:50:00 PMCongressional panels are more about political gamesmanship than truth-finding.
2.4/22/2008 10:03:00 PMno
3.4/22/2008 11:33:00 PMAnd I think Merck will be cleared.
4.4/23/2008 1:35:00 PMThis is congressional grandstanding.
5.4/24/2008 1:31:00 AMother things are more important
6.4/24/2008 11:19:00 AMcongress needs to get out of this business